News from Aptiv, AmerisourceBergen, and AMRI – People on the move
Aptiv Solutions has hired Luis Gutierrez as executive VP and CCO.
He joins the firm from MedAssurant where he was senior VP of pharmaceuticasl and life sciences operations.
Guiterrez will now take charge of business development, as well as marketing and brand management functions at Aptiv.
Of his new role, he said: "I am thrilled to be joining Aptiv Solutions at a time when both regulators and sponsors are becoming increasingly enthusiastic about adaptive clinical trials and are changing requirements for medical device approvals.”
AmerisourceBergen has named Tim Guttman senior VP and chief financial officer, after serving as interim since February.
He has been with the company since 2002, when he joined as VP and corporate controller.
“We have tremendous opportunities ahead, driven by the growth areas of the markets we serve, and the unique services we provide to manufacturers and healthcare providers,” said Guttman.
Albany Molecular Research (AMRI) has made two new appointments to its leadership teams in theUS andSingapore.
Teva’s president and CEO of the AmericasWilliam Marth as joined the board of directors for the overall business.
And Saravanakumar Dhakshinamoorthy will become director of in vitro biology at the firm’sSingapore site as.
The newly created role means the company will have a senior level member of the team inSingapore, rather than theUS.
“Previously the Singapore biology group had been functioning as a satellite operation to AMRI's flagship biology operations in Bothell, US and leadership and oversight of Singapore biology had been handled through Bothell,” said Takeshi Yura, senior director of AMRI Singapore.
“Clients will now have direct senior level access, independent of the US, to help tailor our biology resources to their program and lead and manage the progression of those programs – all self-contained within Singapore."
Anker Lundemose and Nigel Pitchford have joined the board at PolyTherics.
Lundemose is co-founder of several companies including Symphogen, Santaris and Prosidion.
Pitchford is currently managing director of healthcare investments at Imperial Innovations Group.
Chairman Ken Cunningham said: “As PolyTherics makes significant commercial progress with its expanded technology offering and its increasingly successful licensing strategy, these valuable additions to the board set up the company for its next phase of development.”
Healthcare communications agency Pacific Communications has drafted in Emily Alford as account executive.
She previously served in the same role for 3v07 Advertising.
Alford will now join the Botox therapeutic account team.
